# Singapore Company Update



5 May 2022

# Ascendas REIT (AREIT SP)

## A Stable Quarter; Stay BUY

Property | REITS

# Buy (Maintained)

Target Price (Return):	SGD3.60 (27.7%)
Price (Market Cap):	SGD2.82 (USD8,559m)
ESG score:	3.33 (out of 4)
Avg Daily Turnover (SGD/USD)	32.2m/23.5m

## Analysts

## Singapore Research


sg.research@rhbgroup.com

Shekhar Jaiswal +65 6320 0806 shekhar.jaiswal@rhbgroup.com



### Share Performance (%)

YTD	1m	3m	6m	12m
(4.4)	(3.8)	1.1	(9.6)	(9.6)
(11.9)	(2.0)	0.3	(13.9)	(15.2)
v/high (SGD	))		2.76	6 – 3.16
	(4.4) (11.9)	(4.4) (3.8)	(4.4) (3.8) 1.1 (11.9) (2.0) 0.3	$\begin{array}{cccccccccccccccccccccccccccccccccccc$



Source: Bloomberg

## Overall ESG Score: 3.33 (out of 4)

#### E: EXCELLENT

Ascendas REIT has the largest number of BCA Green mark properties (35) total portfolio (43), largest number of public EV charging points (76) and largest combined solar farm (>21,000 solar panels) in Singapore by SREIT. S: GOOD

Its approach to health and safety is guided by its Occupational Health and Safety Management System (OHSMS) accredited to ISO 45001. The group also has internal targets to ensure that at least 92% of vendors (attain a Level 3 in bizSAFE and above) and zero cases of validated discrimination

#### G: EXCELLENT

High level of transparency in financial announcements and earnings releases. Good corporate governance framework.

# • Maintain BUY and SGD3.60 TP, 28% upside with c.6% yield. Ascendas REIT posted a stable set of operational numbers for 1Q22. Overall, the industrial segment's outlook remains relatively resilient across its markets, despite rising global uncertainties and inflationary pressures. We attribute the share price underperformance mainly to investors switching to growth/reopening plays (office/hospitality REITs). However, we believe AREIT's well-diversified and resilient industrial portfolio, with redevelopment potential and a solid 6% yield profile, warrants a relook.

- Healthy 1Q22 positive rent reversion of +4.6% (FY21: +4.5%) with all segments and markets leased during the quarter seeing rent growth Australia (+16.5%), US (+14%), and Singapore (+3.9%). Portfolio occupancy dipped slightly by 0.6ppts to 92.6%, mainly due to non-renewal of two leases in Australia, while occupancy at the UK, Singapore, and US remained relatively stable. The redevelopment of UBIX (formerly 25 & 27 Ubi Road 4) was completed in January for a total cost of SGD38.2m with a pre-committed occupancy of 45% currently. Asset enhancements for Changi Logistics Centre and 17 Changi Business Park Central 1 are in progress, and expected to be completed by 2Q22 and 4Q22 respectively.
- Manageable impact from rising interest rates and utilities. Utility charges for common areas borne by the REIT account for c.8% of opex, and this is expected to rise by 50% this year from higher electricity tariffs. NPI margins are therefore expected to see a 1% squeeze, which we believe can be offset by rent growth. AREIT has also been installing solar panels in its buildings to generate electricity, and as part of its green initiatives. About eight of its 96 assets in Singapore currently have solar panels installed, with another 11 planned this year. About 79% of its debt is hedged with every 20bps rate increase resulting in a modest 0.4% impact.
- Room to unlock value from redevelopments. With the anticipated lifting of Singapore's Data Centre (DC) moratorium later this year, management had previously noted that is sees potential to redevelop some of its light industrial assets in north eastern Singapore into DCs. There is also medium-term potential to unlock value from the gradual redevelopment of its science park assets (c.10% of its portfolio value). Acquisition pace is likely to slow down to c. SGD1b this year, on the back of rising rates, with the focus mainly on logistics, DC, and tech campuses. Gearing is modest at 36.8%, presenting SGD1-2bn debt headroom.
- Maintain estimates. AREIT has the highest ESG score (3.3 out of 4.0) among industrial REITs under our coverage (based on our proprietary methodology), reflecting its strong ESG track record. As the score is three notches above our country median score, we applied a 6% premium to our intrinsic value.

Forecasts and Valuation	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Total turnover (SGDm)	1,049	1,227	1,294	1,327	1,377
Net property income (SGDm)	776	921	968	990	1,017
Reported net profit (SGDm)	457	957	748	588	601
Total distributable income (SGDm)	431	455	506	524	534
DPS (SGD)	0.15	0.15	0.16	0.16	0.17
DPS growth (%)	(5.8)	3.9	4.9	2.8	1.6
P/B (x)	1.16	1.17	1.18	1.18	1.18
Dividend Yield (%)	5.2	5.4	5.7	5.8	5.9
Return on average equity (%)	5.5	10.1	7.5	5.9	6.0
Return on average assets (%)	3.2	5.8	4.2	3.3	3.3
Source: Company data, RHB					



# **Financial Exhibits**

## Property | REITS

Asia	Financial summary	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Singapore	Recurring EPS (SGD)	0.14	0.23	0.18	0.14	0.14
Property	EPS (SGD)	0.13	0.25	0.18	0.14	0.14
Ascendas REIT	DPS (SGD)	0.15	0.15	0.16	0.16	0.17
AREIT SP	BVPS (SGD)	2.43	2.42	2.38	2.38	2.38
Buy	Return on average equity (%)	5.5	10.1	7.5	5.9	6.0
	Weighted avg adjusted shares (m)	3,447.21	3,896.82	4,164.28	4,204.07	4,210.25
Valuation basis						
DDM	Valuation metrics	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
	Recurring P/E (x)	20.07	12.20	15.85	20.39	19.99
Key drivers	P/E (x)	21.27	11.48	15.71	20.16	19.77
i. Diversified industrial assets with high exposure	Р/В (х)	1.2	1.2	1.2	1.2	1.2
to business parks and logistics sector,	FCF Yield (%)	5.7	5.2	9.2	9.4	9.3
ii. Largest and most liquid in S-REIT space, and	Dividend Yield (%)	5.2	5.4	5.7	5.8	5.9
<ol><li>Strong and capable sponsor.</li></ol>	EV/EBITDA (x) -	2.25 -	2.61 -	2.65 -	2.65 -	2.62
	EV/EBIT (x) -	2.26 -	2.61 -	2.65 -	2.65 -	2.62
		2.20 -	2.01 -	2.03 -	2.05 -	2.02
ey risks	Income statement (SGDm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
i. High industrial supply and shorter land leases in						
Singapore;	Total turnover	1,049	1,227	1,294	1,327	1,377
<ul><li>ii. Tenant defaults and rental pressure;</li><li>iii. Government Policy measures impacting</li></ul>	EBITDA Deservición en el concertico dise	702	820	862	883	908
iii. Government Policy measures impacting industrial space.	Depreciation and amortisation	(3)	(0)	0	0	0
	Operating profit	699	820	862	883	908
ompany Profile	Net interest	(159)	(159)	(170)	(181)	(192)
-REIT is a property trust constituted by a trust deed.	Pre-tax profit	494	1,044	783	624	637
-REIT owns and invests in a diverse, income	Taxation	(37)	(86)	(36)	(36)	(37)
roducing portfolio of business park (including science	Recurring net profit	484	901	741	581	594
ark), light industrial, hi-tech industrial and logistic						
roperties in Singapore.	Cash flow (SGDm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
	Change in working capital	20	(83)	153	164	137
	Cash flow from operations	729	727	1,116	1,149	1,148
	Capex	(171)	(159)	(30)	(30)	(50)
	Cash flow from investing activities	(985)	(1,915)	(30)	(30)	(50)
	Dividends paid	(598)	(378)	(506)	(524)	(534)
	Cash flow from financing activities	479	1,277	(1,137)	(1,101)	(1,087)
	Cash at beginning of period	96	278	369	317	335
	Net change in cash	223	89	(51)	18	11
	Ending balance cash	278	369	317	10	
					335	346
		2.0	000	317	335	346
	Balance sheet (SGDm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
	Balance sheet (SGDm) Total cash and equivalents	<b>Dec-20</b> 278	<b>Dec-21</b> 369	Dec-22F 317	Dec-23F 335	<b>Dec-24F</b> 346
	Balance sheet (SGDm) Total cash and equivalents Total investments	Dec-20 278 14,318	Dec-21 369 16,898	Dec-22F 317 17,013	<b>Dec-23F</b> 335 17,128	<b>Dec-24F</b> 346 17,264
	Balance sheet (SGDm) Total cash and equivalents Total investments Total other assets	Dec-20 278 14,318 453	Dec-21 369 16,898 376	Dec-22F 317 17,013 382	Dec-23F 335 17,128 387	Dec-24F 346 17,264 396
	Balance sheet (SGDm) Total cash and equivalents Total investments Total other assets Total assets	Dec-20 278 14,318 453 15,123	Dec-21 369 16,898 376 17,730	Dec-22F 317 17,013 382 17,788	Dec-23F 335 17,128 387 17,929	Dec-24F 346 17,264 396 18,087
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt	Dec-20 278 14,318 453 15,123 226	Dec-21 369 16,898 376 17,730 901	Dec-22F 317 17,013 382 17,788 974	Dec-23F 335 17,128 387 17,929 774	Dec-24F 346 17,264 396 18,087 774
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total long-term debt	Dec-20 278 14,318 453 15,123 226 4,261	Dec-21 369 16,898 376 17,730 901 4,834	Dec-22F 317 17,013 382 17,788 974 4,891	Dec-23F 335 17,128 387 17,929 774 5,191	Dec-24 346 17,264 396 18,087 774 5,291
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt	Dec-20 278 14,318 453 15,123 226	Dec-21 369 16,898 376 17,730 901	Dec-22F 317 17,013 382 17,788 974	Dec-23F 335 17,128 387 17,929 774	Dec-24 346 17,264 396 18,087 774 5,291
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total long-term debt	Dec-20 278 14,318 453 15,123 226 4,261	Dec-21 369 16,898 376 17,730 901 4,834	Dec-22F 317 17,013 382 17,788 974 4,891	Dec-23F 335 17,128 387 17,929 774 5,191	Dec-24F 346 17,264 396 18,087 774 5,291 7,744
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total long-term debt         Total liabilities	Dec-20 278 14,318 453 15,123 226 4,261 5,933	Dec-21 369 16,898 376 17,730 901 4,834 7,453	Dec-22F 317 17,013 382 17,788 974 4,891 7,484	Dec-23F 335 17,128 387 17,929 774 5,191 7,607	Dec-24I 346 17,264 396 18,087 774 5,291 7,744 10,043
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023	Dec-24l 346 17,264 396 18,087 774 5,291 7,744 10,043 299
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299	Dec-24l 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322	Dec-24l 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630	Dec-24 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total labilities         Shareholders' equity         Minority interests         Total equity         Net debt	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt         Total liabilities & equity	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929	Dec-24I 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24I
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt         Total liabilities & equity         Key metrics         Revenue growth (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5,5	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5	Dec-24l 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24l 3,8
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt         Total liabilities & equity         Net debt         Total liabilities & equity         Revenue growth (%)         Recurrent EPS growth (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4 (14.8)	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9 64.5	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5.5 (23.0)	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5 (22.3)	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24F 3.8 2.0
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt         Total liabilities & equity         Net debt         Total liabilities & equity         Revenue growth (%)         Recurrent EPS growth (%)         Operating EBITDA margin (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4 (14.8) 66.9	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9 64.5 66.9	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5.5 (23.0) 66.6	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5 (22.3) 66.5	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24F 3.8 2.0 66.0
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total liabilities & equity         Net debt         Total liabilities & equity         Net debt         Total liabilities & equity         Key metrics         Revenue growth (%)         Recurrent EPS growth (%)         Operating EBITDA margin (%)         Net profit margin (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4 (14.8) 66.9 43.6	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9 64.5 66.9 78.0	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5.5 (23.0) 66.6 57.8	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5 (22.3) 66.5 44.3	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24F 3.88 2.00 66.0 43.6
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total equity         Net debt         Total liabilities & equity         Net debt         Total liabilities & equity         Key metrics         Revenue growth (%)         Operating EBITDA margin (%)         Net profit margin (%)         Dividend payout ratio (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4 (14.8) 66.9 43.6 117.8	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9 64.5 66.9 78.0 65.8	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5.5 (23.0) 66.6 57.8 90.0	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5 (22.3) 66.5 44.3 117.8	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24F 3,88 2,00 66.0 43.6 117.3
	Balance sheet (SGDm)         Total cash and equivalents         Total investments         Total other assets         Total assets         Short-term debt         Total liabilities         Shareholders' equity         Minority interests         Total liabilities & equity         Net debt         Total liabilities & equity         Net debt         Total liabilities & equity         Key metrics         Revenue growth (%)         Recurrent EPS growth (%)         Operating EBITDA margin (%)         Net profit margin (%)	Dec-20 278 14,318 453 15,123 226 4,261 5,933 8,892 299 9,191 4,210 15,123 Dec-20 14,4 (14.8) 66.9 43.6	Dec-21 369 16,898 376 17,730 901 4,834 7,453 9,978 299 10,277 5,366 17,730 Dec-21 16.9 64.5 66.9 78.0	Dec-22F 317 17,013 382 17,788 974 4,891 7,484 10,005 299 10,304 5,548 17,788 Dec-22F 5.5 (23.0) 66.6 57.8	Dec-23F 335 17,128 387 17,929 774 5,191 7,607 10,023 299 10,322 5,630 17,929 Dec-23F 2.5 (22.3) 66.5 44.3	Dec-24F 346 17,264 396 18,087 774 5,291 7,744 10,043 299 10,342 5,719 18,087 Dec-24F 3.88 2.00 66.0 43.6

Source: Company data, RHB



# Ascendas REIT

4 May 2022

# Singapore Company Update


Property | REITS

## Figure 1: AREIT's dividend discount model (DDM) valuation

DDM	FY22F	FY23F	FY24F	FY25F	Terminal value
DDM					
DPU (SGD cents)	16.0	16.5	17.0	17.5	362.3
Fair value (SGD)	3.40				
ESG Premium/(discount)	0.20				
TP (SGD)	3.60				
Current price (SGD)	2.82				
Price upside (%)	27.7				
Distribution yield (%)	5.7				
Total returns (%)	33.4				
Assumptions:					
Risk-free rate (%)	2.8				
Beta	0.7				
Cost of equity (%)	6.4				
Terminal growth (%)	1.5				

Source: RHB

## Figure 2: Portfolio occupancy trend by markets



Source: AREIT

## Figure 3: Continued positive rental reversion across segments and markets

% Change in Renewal Rates for Multi-tenant Buildings <sup>(1)</sup>	1Q FY2022	4Q FY2021	1Q FY2021
Singapore	3.9%	2.3%	2.9%
Business Space <sup>(2)</sup> and Life Sciences <sup>(3)</sup>	3.6%	2.2%	2.8%
Logistics <sup>(4)</sup>	1.5%	3.1%	5.6%
Industrial <sup>(5)</sup> and Data Centres	4.4%	1.8%	-0.3%
Australia	16.5%	_(6)	_(6)
Business Space	16.5%	_(6)	_(6)
Logistics	_(6)	_(6)	_(6)
United States	14.0%	0.9%	6.2%
Business Space	12.2%	18.9%	6.2%
Logistics	26.4%	0.0%	N.A.
United Kingdom/Europe	_(6)	6.2%	_(6)
Data Centres	_(6)	6.2%	_(6)
Logistics	_(6)	_(6)	_(6)
Total Portfolio :	4.6%	2.9%	3.0%

Source: AREIT

See important disclosures at the end of this report



 Percentage change of the average gross rent over the lease period of the renewed leases against the preceding average gross rent from lease start date. Takes into account renewed leases that were signed in their respective periods and average gross rents expected by area reneved.
 Business Space segment includs properties located inbasis segment is business park and office properties in USA properties in USA ready to the segment comprises properties with labready specifications (currently 7 business park properties in Singapore)
 Includes Courts Megastore and Giant Hypermart which have been neclassified from Integrated development, amenties and retail (UAR) segment. These properties have large warehouse spaces (under the Retail Warehouse Scheme).
 Comprises high-specifications cand light industral properties (includes Ageria which has been reclassified from (DAR segment given its predominant industrial space offering).
 There were no renewals signed in the period for the respective segments.

Property | REITS


# **Recommendation Chart**



Date	Recommendation	Target Price	Price
2021-10-20	Buy	3.60	3.04
2021-08-02	Buy	3.50	3.12
2021-03-18	Neutral	3.20	3.07
2021-02-03	Neutral	3.15	3.16
2020-04-19	Neutral	3.00	2.89
2020-02-02	Buy	3.10	3.15
2019-10-10	Neutral	3.00	3.09
2019-03-07	Neutral	2.90	2.78
2018-10-16	Buy	2.90	2.45

Source: RHB, Bloomberg

# **ESG** Rating History





#### **RHB Guide to Investment Ratings**

Buy:	Share price may exceed 10% over the next 12 months
Trading Buy:	Share price may exceed 15% over the next 3 months, however longer-
	term outlook remains uncertain
Neutral:	Share price may fall within the range of +/- 10% over the next
	12 months
Take Profit:	Target price has been attained. Look to accumulate at lower levels
Sell:	Share price may fall by more than 10% over the next 12 months
Not Rated:	Stock is not within regular research coverage

#### **Investment Research Disclaimers**

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB mebsite shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

#### **RESTRICTIONS ON DISTRIBUTION**

#### Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

#### Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

#### Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective informing entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

#### **United States**

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

#### DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

#### Malavsia

Save as disclosed in the following link RHB Research conflict disclosures - Apr 2022 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report. RHBIB is not a market maker in the securities or capital market products of the
- 2 subject company(ies) covered in this report.
- З. None of RHBIB's staff or associated person serve as a director or board member\* of the subject company(ies) covered in this report
- \*For the avoidance of doubt, the confirmation is only limited to the staff of research department
- 4. RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the 5 production of this report.

#### Thailand

- Save as disclosed in the following link <u>RHB Research conflict disclosures Apr 2022</u> and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
  RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
  RHB Securities (Thailand) PCL is not a market maker in the securities or capital for the subject company (ies) covered in this report.
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a 3. director or board member to f the subject company(ies) covered in this report
- 1. \*For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 4. months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including 5. gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

#### Indonesia

Save as disclosed in the following link <u>RHB Research conflict disclosures – Apr 2022</u> and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
  - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report\*; Being bound by an agreement to purchase securities or has the right to
  - b) transfer the securities or has the right to pre subscribe the securities\*
  - Being bound or required to buy the remaining securities that are not c) subscribed/placed out pursuant to an Initial Public Offering\*.
  - d) Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital 2. market products of the subject company(ies) covered in this report. None of PT RHB Sekuritas Indonesia's staff\*\* or associated person serve as a
- 3 director or board member\* of the subject company(ies) covered in this report.
- 4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- 5. PT RHB Sekuritas Indonesia\*\* did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report: Notes:

\*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

\*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

#### Singapore

Save as disclosed in the following link <u>RHB Research conflict disclosures – Apr 2022</u> and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a 1. market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its 2. analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have 4. and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report. RHB Bank Berhad's Singapore research analysts do not receive any
- 6. compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysits.

#### Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



#### **KUALA LUMPUR**

RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia Tel : +603 9280 8888 Fax : +603 9200 2216

#### BANGKOK

RHB Securities (Thailand) PCL 10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand Tel: +66 2088 9999 Fax :+66 2088 9799

#### JAKARTA

PT RHB Sekuritas Indonesia Revenue Tower, 11th Floor, District 8 - SCBD JI. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia Tel : +6221 509 39 888 Fax : +6221 509 39 777

#### SINGAPORE

## RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470

